Clinical impact of delaying initiation of adjuvant chemotherapy in patients with early triple negative breast cancer

URN to cite this document:: urn:nbn:de:bvb:355-epub-554061
DOI to cite this document:: 10.5283/epub.55406

Hatzipanagiotou, Maria Eleni

; Pigerl, Miriam ; Gerken, Michael ; Räpple, Sophie ; Zeltner, Verena ; Hetterich, Madeleine ; Ugocsai, Peter ; Inwald, Elisabeth Christine ; Klinkhammer-Schalke, Monika ; Ortmann, Olaf

; Seitz, Stephan

License: Creative Commons Attribution 4.0
PDF - Published Version
(630kB)

Date of publication of this fulltext: 25 Jan 2024 05:16

Alternative links to fulltext:DOI Publisher

This publication is part of the DEAL contract with Springer.

Details

Preview

Export bibliographical data

Abstract

Purpose The optimal time to initiation of adjuvant chemotherapy (TTAC) for triple negative breast cancer (TNBC) patients is unclear. This study evaluates the association between TTAC and survival in TNBC patients. Methods We conducted a retrospective study using data from a cohort of TNBC patients diagnosed between January 1, 2010 to December 31, 2018, registered in the Tumor Centre Regensburg ...